Richter's Transformation Archives

August 17, 2022

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.

July 6, 2022

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

Discussion of new results from a phase 1 clinical trial of the atezolizumab plus immunogenic chemotherapy. Atezolizumab is a checkpoint inhibitor that blocks PD-L1, a checkpoint protein found on cancer cells. It is already approved for use in treating certain types of bladder cancers and lung cancers.

June 9, 2022

ASH 2021: Dr. Alexey Danilov on Richter’s Transformation After CAR-T Therapy

and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.

May 20, 2022

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.

July 8, 2021

EHA 2021: Dr. Anthony Mato on pirtobrutinib (LOXO-305) for Richter’s transformation in chronic lymphocytic leukemia (CLL)

At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center. They discussed preliminary results from a clinical trial of pirtobrutinib (formerly LOXO-305) in a subset of patients with

April 15, 2021

ASH 2020: Dr. Arnon Nagler on Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation After Targeted Therapy for Chronic Lymphocytic Leukemia (CLL)

July 24, 2020

ASCO 2020 Top 12” #3: A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome

A multi-center phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome

March 9, 2020

ASH 2019: Dr. Mato Discusses a Novel Triple Therapy Clinical Trial for CLL/SLL, Richter’s Transformation and other Lymphomas

In this interview, Dr. Mato discusses a Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel Bruton’s Tyrosine Kinase Inhibitor; DTRMWXHS-12 (DTRM-12), in combination with Everolimus (Afinitor®) and Pomalidomide (Pomalyst®) in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas.

December 7, 2019

ASCO 2019: CLL Society Dr. Koffman’s Pick #7 “Stem Cell Transplant in Richter Transformation inn Chronic Lymphocytic Leukemia (CLL)”

Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society of Clinical Oncology Annual Meeting held May 31 – June 4, 2019, Chicago, IL. #7 Outcomes of stem

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Richter’s Transformation

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

ASH 2021: Dr. Alexey Danilov on Richter’s Transformation After CAR-T Therapy

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

EHA 2021: Dr. Anthony Mato on pirtobrutinib (LOXO-305) for Richter’s transformation in chronic lymphocytic leukemia (CLL)

ASH 2020: Dr. Arnon Nagler on Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation After Targeted Therapy for Chronic Lymphocytic Leukemia (CLL)

ASCO 2020 Top 12” #3: A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome

ASH 2019: Dr. Mato Discusses a Novel Triple Therapy Clinical Trial for CLL/SLL, Richter’s Transformation and other Lymphomas

ASCO 2019: CLL Society Dr. Koffman’s Pick #7 “Stem Cell Transplant in Richter Transformation inn Chronic Lymphocytic Leukemia (CLL)”

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT